Company intelligence / Profile preview

Immunebro Therapeutics

Ownership: Private
Development stage: Preclinical

Overview

Developing engineered allogeneic T cells that aim to surpass autologous CAR T cells in simplicity, safety, and efficacy. Current development is in pre-clinical stage.

Therapeutic areas: Oncology
Modalities: Engineered allogeneic T cellsEngineered B cell therapeutics
Industry: Biotech

Drug pipeline

1 asset

IBT1116

Preclinical

Beyond the preview

Go deeper on Immunebro Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunebro Therapeutics.

Explore the full profile